Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients

Completed · Phase 2 · Has a placebo group

Conditions studied: Epidermolysis Bullosa, Pruritus

In brief

Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).

Key facts

Study ID

NCT02654483

Run by

Jean Yuh Tang

People needed

14

Starts

2016-08-31

Expected to finish

2018-07-27

Last updated by the study team

2020-03-23

Who can join

Age: 13 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of Epidermolysis Bullosa (EB) and pruritus

You may not qualify if…

• Chronic liver or renal disease

Where it is running

• Stanford — Stanford, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.